Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ER α ), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews t...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2010-05, Vol.23 (Suppl 2), p.S52-S59
Main Author: Allred, D Craig
Format: Article
Language:English
Subjects:
692/53
692/699/67/1347
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Estrogen Receptor alpha - biosynthesis
Estrogen Receptor alpha - genetics
Female
Genes, erbB-2
Genetic Predisposition to Disease
Humans
Immunohistochemistry
Laboratory Medicine
long-course-article
Medicine
Medicine & Public Health
Pathology
Receptor, ErbB-2 - biosynthesis
Receptor, ErbB-2 - genetics
Receptors, Progesterone - biosynthesis
Receptors, Progesterone - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ER α ), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ER α , PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.2010.55